SP-0610: Will targeted agents improve the results of chemoradiation in high-risk HPV-negative head and neck cancers?

2014 ◽  
Vol 111 ◽  
pp. S238
Author(s):  
E. Deutsch ◽  
Y. Tao ◽  
P. Blanchard ◽  
S. Rivera ◽  
J.L. Perfettini
2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e13566-e13566
Author(s):  
N Mullai ◽  
Soleiman Osman ◽  
Joseph Rattenni

e13566 Background: Human papilloma virus (HPV) is the most common sexually transmitted agent and has extensive association with many malignancies such as cervical, vaginal, vulvar, penile, and head and neck cancers. Vaccination helps prevent sexually transmitted diseases due to HPV. In addition, it provides protection against cancers caused by persistent, high-risk HPV infection in both male and female. Methods: Data collected from the medical records of patients diagnosed with anogenital, and head and neck cancers during 2017-2019 were studied retrospectively and the association of HPV infection was analyzed. Results: There were thirty-three cases of anogenital, and head and neck cancers diagnosed during the study period. The following were the occurrences: penile cancer 1, anal cancer 4, cervical/uterine/vaginal cancers 10, and head and neck cancer including tonsil, base of tongue, vocal cord, and glottis 18. HPV status was available in twenty-six (79%) patients. Fourteen patients were positive for high-risk 16/18 HPV strain, twelve were HPV negative, and HPV status was unknown for seven patients. Most of the patients were smokers and none of them had received HPV vaccination. The patients were treated appropriately with chemotherapy, radiation, and surgery. Conclusions: Human papilloma virus (HPV) infection type 16/18 is the most common sexually transmitted infection associated with significant anogenital and head and neck cancers.Vaccinations protect against persistent, high-risk HPV infection that may lead to malignancies. However, the HPV vaccination initiation and completion rates are only 41.7% and 21.6% respectively in males, and 60% and 39.7% respectively in females. The lack of opportunity does not appear to be a major reason for this low coverage. Some of the barriers for low adoption of HPV vaccination were concern about vaccine safety (70%), lack of knowledge about HPV related diseases (56%), very young to vaccinate (56%), fear of riskier sexual behavior (56%), and reluctance as not being included in the required immunization schedule (71%). In addition, several people refused HPV vaccination due to misinformation in social media. The primary purpose of HPV vaccination is to help prevent sexually transmitted diseases. Further, such vaccination can also prevent several cancers caused by persistent infection. Therefore, HPV vaccination has the potential to eliminate such risk if enforced at a young age in school. The above study and data stress this role and the importance of public awareness of the HPV vaccine as a cancer prevention agent.


Pathology ◽  
2017 ◽  
Vol 49 (5) ◽  
pp. 494-498 ◽  
Author(s):  
Laveniya Satgunaseelan ◽  
Noel Chia ◽  
Hyerim Suh ◽  
Sohaib Virk ◽  
Bruce Ashford ◽  
...  

2020 ◽  
Vol 11 (10) ◽  
pp. 637-651 ◽  
Author(s):  
Swatantra Shrivastava ◽  
Ravleen Nagi ◽  
Saurabh Sharma ◽  
Sajid Ahmed Rasul Sanadi ◽  
Elbadri Taha Dafallah ◽  
...  

Cancer is a major public health burden worldwide, affecting millions of people each year. One of the major hallmarks of cancer is rapid growth and progression by evasion of host immune responses. Tumor resistance to conventional anticancer drugs by several mechanisms, such as drug inactivation, efflux pumps and enhanced toxicity to normal cells decreases their clinical efficacy. These limitations resulted in the development of new targeted agents, such as monoclonal antibodies and small molecule inhibitors that have high tumor specificity. This paper discusses the therapeutic applications of novel molecular targeted agents and immunotherapy as an alternative treatment option for head and neck cancers, as well as provides insight into future therapeutic approaches for advanced head and neck cancers.


PLoS ONE ◽  
2015 ◽  
Vol 10 (10) ◽  
pp. e0140700 ◽  
Author(s):  
Rupesh Kumar ◽  
Avdhesh Kumar Rai ◽  
Debabrata Das ◽  
Rajjyoti Das ◽  
R. Suresh Kumar ◽  
...  

2019 ◽  
Vol 122 (3) ◽  
pp. 306-314 ◽  
Author(s):  
Maria Elisa Sabatini ◽  
Susanna Chiocca

Abstract The human papillomavirus (HPV) family includes more than 170 different types of virus that infect stratified epithelium. High-risk HPV is well established as the primary cause of cervical cancer, but in recent years, a clear role for this virus in other malignancies is also emerging. Indeed, HPV plays a pathogenic role in a subset of head and neck cancers—mostly cancers of the oropharynx—with distinct epidemiological, clinical and molecular characteristics compared with head and neck cancers not caused by HPV. This review summarises our current understanding of HPV in these cancers, specifically detailing HPV infection in head and neck cancers within different racial/ethnic subpopulations, and the differences in various aspects of these diseases between women and men. Finally, we provide an outlook for this disease, in terms of clinical management, and consider the issues of ‘diagnostic biomarkers’ and targeted therapies.


2016 ◽  
Vol 15 (2) ◽  
pp. 179-188 ◽  
Author(s):  
Heather M. Walline ◽  
Thomas E. Carey ◽  
Christine M. Goudsmit ◽  
Emily L. Bellile ◽  
Gypsyamber D'Souza ◽  
...  

Author(s):  
Chameera Ekanayake Weeramange ◽  
Zhen Liu ◽  
Gunter Hartel ◽  
Yinan Li ◽  
Sarju Vasani ◽  
...  

2015 ◽  
Vol 23 (4) ◽  
pp. 266-272 ◽  
Author(s):  
Jody E. Hooper ◽  
Jessica F. Hebert ◽  
Amy Schilling ◽  
Neil D. Gross ◽  
Joshua S. Schindler ◽  
...  

2017 ◽  
Vol 141 (1) ◽  
pp. 143-151 ◽  
Author(s):  
Tarik Gheit ◽  
Devasena Anantharaman ◽  
Dana Holzinger ◽  
Laia Alemany ◽  
Sara Tous ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document